IDH2 and acute myeloid leukemia: These include a phase II trial in pediatric patients with R/R AML with IDH2-mutations (NCT04203316), a phase II trial in R/R AML patients with IDH2 mutations to investigate whether enasidenib can be used as maintenance therapy post salvage induction therapy (NCT03881735), and two other phase II trials investigating the use of enasidenib in the treatment of MDS as a monotherapy or in combination with azacitidine (NCT03744390, NCT03383575).